Clinical Trial Update: Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating switching HIV patients from enfuvirtide to a darunavir/ritonavir-based regimen plus etravirine due to enfuvirtide-related side effect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Fuzeon (enfuvirtide)
• Intelence (Etravirine)
• Norvir (ritonavir)
• PREZISTA (darunavir)

Snippet

Sponsor: Tibotec, Inc | Conditions: HIV | Phase 3 | Status: COMPLETED | Results posted: 2009-11-10